Donor CAR-T cells for hard-to-treat Graves' disease
Treatments studied
Part of Eyes & vision, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new type of cell therapy called CAR-T cells made from a donor. The cells target B cells that may drive Graves' disease. It's for people whose Graves' disease has not gotten better with usual treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Graves' disease that hasn't improved with standard treatments (after years of medication or multiple radioiodine treatments).
- Your TRAb level (a blood test for thyroid antibodies) is at least 5 IU/L.
- You have B cells (a type of white blood cell) that carry a marker called CD19.
- You are willing to sign a consent form and follow the study schedule.
- You do not have other serious health issues like active infections, heart disease, or cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests whether specially engineered immune cells (called CAR-T) can treat Graves' disease that hasn't responded to standard medication. It's for people with active, hard-to-control Graves' who have the TRAb antibody.
This early-phase trial tests a new type of treatment called CAR-T cells (special immune cells made in a lab) to target and calm down the overactive immune system in people with severe Graves' disease that hasn't improved with standard medicines. It may offer a new option for those who have been on treatment for years or have had multiple relapses.
This trial tests whether CAR-T cells made from a healthy donor can help treat B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. It's for adults who cannot use their own cells for CAR-T therapy.
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
This trial tests a new treatment made from donor cells that target two proteins (CD19 and CD20) found on certain blood cancer cells. It may be an option for people whose B-cell lymphoma or chronic lymphocytic leukemia has come back or hasn't responded to at least two prior treatments.
This trial tests a new type of CAR-T cell therapy for people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard treatment. The CAR-T cells are made from a donor and modified to target the CD19 protein on leukemia cells.
Hear when a new Graves Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.